+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years - 130Years
All Genders
ID06651970

Open-label Randomized Study Comparing Acalabrutinib Monotherapy to Investigators Choice in Adults with Chronic Lymphocytic Leukemia and Moderate to Severe Heart Impairment

Led by AstraZeneca · Updated on 2026-09-24

60

Participants Needed

23

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a global Phase IV, open-label, randomized study to evaluate the safety and tolerability of acalabrutinib monotherapy compared to the investigators choice of treatment in adults with chronic lymphocytic leukemia CLL who also have moderate to severe heart problems. This study focuses on patients with significant cardiac impairment who might have been excluded from previous trials, aiming to better understand the safety profile of acalabrutinib in this specific group. The study involves collaboration between hematology and cardiology specialists, including cardio-oncologists. Participants will be randomly assigned to receive either acalabrutinib tablets taken orally twice daily or a treatment chosen by the investigator, which may include medications such as chlorambucil, venetoclax, or rituximab. Treatment cycles last 28 days, with initial frequent evaluations during the first eight cycles and less frequent assessments thereafter. Cardiology evaluations include consultations, echocardiograms, ECGs, Holter monitoring, and cardiac biomarker tests at specific intervals, with cardiac MRI performed yearly. Treatment continues until unacceptable side effects or disease progression. During the study, participants will have regular visits for blood tests, physical exams, and response assessments based on established criteria. Safety evaluations, especially for heart-related events, will be conducted throughout treatment and after discontinuation, with follow-up visits continuing until disease progression, withdrawal, death, or study end. Researchers will monitor cardiovascular adverse events leading to treatment changes, serious cardiac events, and overall survival, with follow-up lasting up to four years from the last participants enrollment.

CONDITIONS

Brief Title

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here